Detection and Molecular Characterization of Circulating Tumor C ells (CTCs) in Patient with Metastatic Melanoma: A Potential Applica tion of Liquid BiopsySuresh M Kumar*
Department of Science, Engineering and Technology, The Pennsylvania State University, West Harrisburg, USA
- *Corresponding Author:
- Dr. Suresh M Kumar
PhD, Department of Science
Engineering and Technology
777 The Pennsylvania State University
West Harrisburg Drive, Middletown
PA 17057, USA
E-mail: [email protected]
Received date: May 26, 2016; Accepted date: June 10, 2016; Published date: June 17, 2016
Citation: Kumar SM (2016) Detection and Molecular Characterization of Circulating Tumor Cells (CTCs) in Patient with Metastatic Melanoma: A Potential Application of Liquid Biopsy. Clin Med Biochemistry Open Access 2: 119. doi:10.4172/2471- 2663.1000119
Copyright: © 2016 Kumar SM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Melanoma specific anti NG2 antibody conjugated with iron oxide nanoparticles that have been developed to isolate, detect, and culture CTCs from melanoma xenograft models and blood from patients with metastatic melanoma. The enrichment process involved, lysis of RBC from blood samples using RBC lysis buffer enhances the cancer cell recovery by immunomagnetic labeling and separation. Efficient cell capture was validated using fluorescently labeled cancer cells spiked into healthy human blood and clinical utility was demonstrated in specimens from patient with metastatic melanoma. The spiking experiment results with greater than 70% recovery in four sets of experimental. Spontaneous metastasis melanoma model, found that the number of CTCs increased during the tumor progression and correlated to lymphatic as well as lung metastasis development in vivo. CTCs were detected in 6 out of 7 patients’ blood samples that contained metastatic melanoma. The CTCs were positive for melanoma specific molecular markers such as S100, HMB45, MelaA, MITF and the CTCs were positive for anti NG2-Q-dot and pERK2-Q-dot staining. The BRAFV600e gene expression pattern resulted that the CTCs were expressed BRAFV600e similar to the control melanoma cells. The iron oxide antibody nanoparticle isolation method is a highly reliable and cost effective detection method of CTCs from patients with metastatic melanoma and CTCs cells can be culture for additional analytical studies or potential drug sensitivity testing.